Pfizer and BioNTech are targeting the oncology market for growth while continuing their COVID-19 vaccine development.
3 reports, 2 independent
Updated Sep 15
Gone quiet
- Reports
- 3
- Developments
- 1
- Repetition
- 67%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Pfizer and BioNTech are targeting the oncology market for growth while continuing their COVID-19 vaccine development.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Pfizer
American multinational pharmaceutical and biotechnology corporation
Related events
- FDA granted approval for Pfizer's updated vaccine on September 2, 2025.
- Pfizer and Seagen are growing their older-adult vaccine market share by expanding the Prevnar 20 vaccination program and rebuilding their commercial model around acquired products.
- Pfizer, Novartis, Merck, and Intravacc are competing in the high-cost gene therapy market, utilizing specialized manufacturing and vaccine production services.
- The FDA has approved the XFG variant formula for U.S. use, and Pfizer is now deploying the approved vaccine doses across the United States.
- The discussion centers on the differing views regarding vaccines and how Albert Bourla is navigating the company through various market pivots.